Ninth AACR-Japanese Cancer Association Joint Conference:
Breakthroughs in Basic and Translational Cancer Research
February 21-25, 2013
Hyatt Regency Maui
Maui, HI
CONFERENCE CO-CHAIRPERSONS:
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA
Kohei Miyazono, University of Tokyo, Tokyo, Japan
More than 20 years ago, the American Association for Cancer Research and the Japanese Cancer Association held their first of eight joint conferences. These meetings have been aimed at bringing outstanding American and Japanese researchers together with two goals. The first is to provide a forum for discussion of the latest advances in the broad field of cancer research, both translational/clinical and basic. The second and equally important goal is to provide a mechanism for the interpersonal interactions which foster international collaborations. These conferences have been extremely successful in both areas and are tangible examples of the close relationship between the AACR and the JCA.
The Ninth Joint Conference continues to extend this tradition. The 12 conference sessions will feature outstanding speakers covering topics ranging from basic science to therapeutics, including prevention, epigenetics and other important areas. Thus, the conference will take a broad view of contemporary cancer research that is intended to be of interest to basic and clinical investigators. The organization and timing of the platform and poster sessions have been designed to maximize interactions. The conference organizers believe that this meeting will catalyze many new collaborations, just as its predecessors have done.
ORGANIZING COMMITTEE:
Lynda Chin, The University of Texas MD Anderson Cancer Center, Houston, TX, USA (AACR)
Lisa M. Coussens, Oregon Health & Science University Knight Cancer Institute, Portland, OR, USA (AACR)
Mari Kannagi, Tokyo Medical & Dental University, Tokyo, Japan (JCA)
Gou Young Koh, Korea Advanced Institute, Daejeon, Korea (Rep.) (JCA)
Sean J. Morrison, UT Southwestern Medical Center, Dallas, TX, USA (AACR)
Hitoshi Nakagama, National Cancer Center Research Institute, Tokyo, Japan (JCA)
Tomoki Naoe, Nagoya University Hospital, Nagoya, Japan (JCA)
Motoharu Seiki, University of Tokyo, Institute of Medical Science, Tokyo, Japan (JCA)
Jeffrey E. Settleman, Genentech Inc., South San Francisco, CA, USA (AACR)
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA (AACR)
Program as of May 11
Keynote Addresses
RNA biology and basic and translational cancer research
Phillip A. Sharp, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA
Targeting essential growth drivers in human cancers
Hiroyuki Mano, Jichi Medical School, Tochigi, Japan
|
Signaling and Systems Biology
Targeted sequencing of Asian cancer phenotypes
Patrick Tan, Duke-NUS Graduate Medical School Singapore, Singapore
Title to be announced
Joe W. Gray, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA
Statistical gene network analysis for understanding cancer heterogeneity
Seiya Imoto, University of Tokyo, Institute of Medical Science, Tokyo, Japan
|
Circulating Tumor Cells and Other New Diagnostic Technologies
Bioengineering and clinical applications of circulating tumor cell chip
Shyamala Maheswaran, Massachusetts General Hospital, Charlestown, MA, USA
PLS3 expression in circulating blood is a good marker for colon cancer recurrence
Masaki Mori, Osaka University, Osaka, Japan
The clinical application of circulating tumor DNA
Luis A. Diaz, Johns Hopkins Kimmel Comprehensive Cancer Center, Baltimore, MD, USA
|
Cancer Genomes and Tumor Evolution
Survival of the fittest: Cancer genome evolution towards adaptation
Tatsuhiro Shibata, National Cancer Center Research Institute, Tokyo, Japan
Interrogating the architecture of cancer genomes
Peter J. Campbell, Wellcome Trust Sanger Institute, Cambridge, United Kingdom
Genome-wide analyses of pediatric solid tumors
Junko Takita, University of Tokyo, Tokyo, Japan
|
Preclinical Models
GEM models in translational research
Lynda Chin, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
Novel strategies for targeting cancer stem cells
Hideyuki Saya, Keio University, Tokyo, Japan
Contributions of the tumor microenvironment to chemoresistance
Mikala Egeblad, Cold Spring Harbor Laboratory, Cold Spring Harbor, NY, USA
|
Cancer Progression and Metastasis
Title to be announced
Tyler Jacks, David H. Koch Institute for Integrative Cancer Research at MIT, Cambridge, MA, USA
Significance of hypoxia-inducible factor in cancer progression and metastasis
Shinae Kondoh, Tokyo Institute of Technology, Tokyo, Japan
The systemic environment as an important determinant of malignancy
Sandra S. McAllister, Brigham and Women's Hospital, Boston, MA, USA
|
Noncoding RNAs
Senescence-associated microRNAs, a novel approach to tumor suppression
Hidetoshi Tahara, Hiroshima University, Hiroshima, Japan
Linking RNA to human health and disease
John Rinn, Harvard University, Cambridge, MA, USA
|
Targeted Therapies and Resistance
Title to be announced
Jeffrey E. Settleman, Genentech, Inc., South San Francisco, CA, USA
TTF-1: A double-edged sword in lung adenocarcinoma
Takashi Takahashi, Nagoya University, Nagoya, Japan
Biological mechanisms of resistance to targeted therapies
Katerina A. Politi, Yale Cancer Center, New Haven, CT, USA
|
Cancer Immunology and Immunotherapy
Title to be announced
James Allison, Memorial Sloan-Kettering Cancer Center, New York, NY, USA
Impact of innate and acquired immune responses in adult T-cell leukemia
Mari Kannagi, Tokyo Medical and Dental University, Tokyo, Japan
|
Epigenetics and Cancer Cell States
Epigenetic plasticity and its clinical implications in human neoplasia
Yutaka Kondo, Aichi Cancer Center, Nagoya, Japan
The regulation of melanoma metastasis
Sean Morrison, UT Southwestern Medical Center, Dallas, TX, USA
Dysregulation of noncoding RNA genes and its clinical application
Hiromu Suzuki, Sapporo Medical University, Sapporo, Japan
|
Cancer Prevention
Energy balance and inflammation in cancer prevention and prognosis
Kornelia Ulrich, German Cancer Research Center, Heidelberg, Germany
GWAS revealed the roles of gene-environmental interaction in carcinogenesis
Koichi Matsuda, University of Tokyo, Institute of Medical Science, Tokyo, Japan
Targeting the DNA repair network as a novel approach for cancer prevention
Guang Peng, The University of Texas MD Anderson Cancer Center, Houston, TX, USA
|
Tumor Microenvironment
Molecular control of tumor vessel destabilization
Gou Young Koh, Korea Advanced Institute of Science and Technology (KAIST), Daejeon, Korea
Chronic inflammation and cancer: Translating basic science to the clinic
Lisa M. Coussens, Oregon Health & Science University's Knight Cancer Institute, Portland, OR, USA
Mint3 promotes tumor malignancy in cancer and stromal cells
Takeharu Sakamoto, University of Tokyo, Institute of Medical Science, Tokyo, Japan
|
DNA Damage Response
DNA damage response and cellular senescence in cancer
Eiji Hara, Japanese Foundation for Cancer Research, Tokyo, Japan
Harnessing genetic dependencies in cancer therapy
Alan Ashworth, Institute of Cancer Research, London, United Kingdom
Complex regulation of homologous recombination by E3 ligases
Shin-ichiro Nakada, Keio University, Tokyo, Japan
|